绝经期激素治疗与类风湿关节炎风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项观察性研究、共22,291,843人年随访,评估绝经后女性使用绝经期激素治疗与类风湿关节炎(RA)发病的关联。汇总结果显示,激素治疗使用与RA风险轻度升高相关(Rate Ratio 1.15,95%CI 1.10-1.21,p<0.001;I²=0%),当前使用者和长期使用(≥4年)者风险更高,提示需个体化评估风险与获益。
要点
- 绝经期激素治疗与RA风险轻度升高相关,汇总Rate Ratio为1.15。
- 当前使用者RA风险高于既往使用者,长期使用(≥4年)风险进一步升高。
- 绝对风险增幅小,但对自身免疫易感女性应个体化权衡风险与获益。
核心结论
- 绝经期激素治疗使用与绝经后女性类风湿关节炎发病率轻度升高相关,当前使用及长期使用风险更高。
研究设计与样本
- 遵循PRISMA指南的系统综述与荟萃分析,检索MEDLINE、Embase和Cochrane Library至2025年10月,纳入评估绝经期激素治疗与RA风险的观察性研究。
- 共纳入5项研究,累计22,291,843人年随访,采用随机效应模型计算汇总风险比(RR)及95%CI。
主要发现
- 总体激素治疗使用与RA风险轻度升高相关(Rate Ratio 1.15,95%CI 1.10-1.21,p<0.001;I²=0%)。
- 当前使用者Rate Ratio 1.18(95%CI 1.00-1.37,p=0.04),既往使用者Rate Ratio 1.11(95%CI 0.94-1.32,p=0.20)。
- 长期使用(≥4年)者风险更高(Rate Ratio 1.19,95%CI 1.07-1.33,p=0.002)。
关键数值与推荐
- 总体汇总Rate Ratio 1.15(95%CI 1.10-1.21,p<0.001;I²=0%)。
- 当前使用Rate Ratio 1.18(95%CI 1.00-1.37,p=0.04);既往使用Rate Ratio 1.11(95%CI 0.94-1.32,p=0.20)。
- 长期使用(≥4年)Rate Ratio 1.19(95%CI 1.07-1.33,p=0.002)。
临床怎么用
- 对绝经后女性处方绝经期激素治疗时,应结合自身免疫易感性个体化评估风险与获益。
- 对有RA易感因素者,可关注激素治疗使用及疗程,并在随访中留意RA相关症状。
局限性
- 纳入研究均为观察性研究,可能存在混杂与偏倚。
- 仅纳入5项研究,亚组分析(当前与既往使用、疗程)证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between menopausal hormone therapy use and Rheumatoid Arthritis (RA) incidence among postmenopausal women. METHODS: A systematic review and meta-analysis were conducted following PRISMA guidelines. MEDLINE, Embase, and the Cochrane Library were searched up to October 2025 for observational studies evaluating menopausal hormone therapy use and RA risk. Pooled risk ratios (RR) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses explored current versus former use and therapy duration. RESULTS: Five studies comprising 22,291,843 person-years of follow-up were included. Overall, menopausal hormone therapy use was associated with a modestly increased RA risk (Rate Ratio 1.15, 95% CI 1.10-1.21, p < 0.001; I² = 0%). Current users had higher risk (Rate Ratio 1.18, 95% CI 1.00-1.37, p = 0.04) compared with former users (Rate Ratio 1.11, 95% CI 0.94-1.32, p = 0.20). Long-term use (≥4 years) conferred greater risk (Rate Ratio 1.19, 95% CI 1.07-1.33, p = 0.002). CONCLUSIONS: Current menopausal hormone therapy use is associated with a modestly higher incidence of rheumatoid arthritis. Although the absolute increase is small, the widespread use highlights the need for individualized risk-benefit assessment, especially in women with autoimmune susceptibility.
引用
- Guimarães C, Balbinot E, Marçal F, et al. Hormone therapy in menopause increases rheumatoid arthritis risk: A systematic review and meta-analysis. Semin Arthritis Rheum. 2026. PMID: 41619569. doi:10.1016/j.semarthrit.2026.152935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。